Background. Lung transplants, in particular, have the highest rate of infections among solid organ transplant recipients. However, there is no existing objective measure to predict the development of infections. We report the correlation between Cylex ImmuKnow (ng/mL ATP) values and various infectious syndromes in a large prospective cohort of lung transplant recipients. Methods. We followed up 175 lung transplants that developed 129 infectious episodes. Multiple logistic regression analysis was performed; generalized estimating equations were used to determine the odds ratio for infections. Results. The median ImmuKnow values in cytomegalovirus disease (49.3 ng/mL ATP), viral infection (70 ng/mL ATP), and bacterial pneumonia (92 ng/mL ATP) were significantly different from stable state (174.8 ng/mL ATP). The median ImmuKnow values of fungal disease (85 ng/mL ATP) and tracheobronchitis (123 ng/mL ATP) had a tendency to be lower than stable state (Pϭ0.10), whereas patients with fungal colonization had comparable ImmunKnow values (167 vs. 174.8 ng/mL ATP). Of the patients colonized with fungus who subsequently developed fungal disease within 100 days, the median value of ImmuKnow was significantly lower than in those who did not develop fungal disease (22.5 vs. 183.5 ng/mL ATP; PϽ0.0001). Generalized estimating equation regression analysis showed ImmuKnow values less than or equal to 100 ng/mL ATP to be an independent predictor of infections (odds ratio 2.81). Conclusions. Cylex ImmuKnow assay monitoring has the potential to identify the patients at risk of developing infection and those colonized with fungus that are at risk of developing disease.
O rgan transplantation is an established mode of therapy for the patients with end-stage organ disease. Although significant strides have been made in improving the outcome in organ recipients, infections are still a common and important cause of morbidity and mortality in these individuals. The immune system is a dynamic interplay of positive and negative regulatory responses that are affected by the patient's individual response to immunosuppressive drugs, underlying clinical condition, diet, genetic background, gender, age, and new allograft (1) . The heightened susceptibility of infection of these individuals is related to the "net state of immunosuppression" induced by the use of immunosuppressive agents primarily directed against T cells (2) (3) (4) (5) . However, the optimal objective measurement of net state of immunosuppression is lacking. There is a need for the accurate quantification of this state to predict the development of infectious syndromes.
The Cylex ImmuKnow assay is approved by US Food and Drug Administration for detecting cell-mediated immunity in an immunosuppressed patient. ImmuKnow measures T-cell responses against a pan-T-cell mitogen, phytohemaglutinin, thereby providing a gauge of recipient global T-cell responsiveness (6) . We hypothesized that the global immunoreactivity as measured by ImmuKnow would be different among patients with various infectious syndromes in lung transplant recipients. In this study, we prospectively monitored the Cylex ImmuKnow values in 175 lung transplant recipients and correlated their level of response with various infectious syndromes. Our data suggest that Cylex Im-muKnow value of less than 100 ng/mL ATP obtained within 1 month of infection may be an independent predictor for the development of infectious syndromes in lung transplant recipients.
METHODS
A total of 175 consecutive lung transplant recipients who were transplanted between January 2003 and September 2006 were prospectively enrolled in the study. The blood and clinical data were collected as a part of prospective infectious complication surveillance study in the lung transplant recipients. ImmunKnow monitoring was performed when the patients presented for routine clinical appointment or bronchoscopy. They were also performed when they had unscheduled or urgent clinical appointment, hospitalization, or bronchoscopy. The test results were not used in the management of patients.
The institutional review board approved the study, and informed consent was obtained from each patient before the study entry (Clinical Trial.gov NCT00177918).
Immunosuppression
All patients received alemtuzumab induction followed by tacrolimus and prednisone monotherapy as described earlier (7, 8) . Acute rejection episodes were treated with methylprednisolone or an oral prednisone taper. Antithymocyte globulin, alemtuzumab, or OKT3 were used for corticosteroid resistant rejection.
Definitions
All infectious syndromes were classified as per standardized criteria (9) . The rejection episodes were classified as per The International Society for Heart & Lung Transplantation criteria (10) . Only Cylex ImmuKnow values drawn within a month before various infectious syndromes were categorized as values related to infection for analysis. Patients were labeled stable when no infection or rejection was noted a month before or after the blood for Cylex ImmuKnow was drawn. The values of Cylex ImmuKnow were not used in management decisions.
Prophylaxis
All patients received valganciclovir 450 mg twice daily (with dosage adjusted for renal dysfunction) as cytomegalovirus (CMV) prophylaxis. Valganciclovir was continued for 6 months in CMV seronegative recipients of seropositive allografts and for 3 months in all others. Antifungal prophylaxis was used with oral voriconazole 200 mg twice daily for 4 months. Trimethoprim-sulfamethoxazole single strength every other day was used for pneumocystis (carinii) jiroveci pneumonia (PCP) prophylaxis. Patient allergic to trimethoprim-sulfamethoxazole were placed on dapsone.
Test Performance
A total of 710 blood samples were assayed with follow-up from 2 to 48 months. Sodium heparin anticoagulated whole blood samples were collected during routine or unscheduled clinic or in-hospital visits. Immune responses were measured using an US Food and Drug Administration-approved assay for T-cell function, ImmuKnow (Cylex, Columbia, MD) according to the manufacturer's instructions (11) .
Statistical Analyses
Nonparametric (Kruskal-Wallis or Mann-Whitney tests) were used for continuous variables, whereas Fisher exact or chi-square test was used for categorical variables. Stata 8 (Stata Corp LP, College Station, TX) was used for group analysis. Because all observations within a patient are correlated, we used the generalized estimating equations (GEE) for the regression analysis (SAS, Cary, NC). The predictor variables used for univariate analysis included age greater than 50 years, gender, race (white vs. others), type of transplant (single/double), cystic fibrosis, Cylex value equal or less than 100 ng/mL ATP, primary CMV mismatch (Dϩ/RϪ), and tacrolimus value greater than 20 within a month before test. GEE models were generated with dependent variable of all infections, bacterial infections, fungal infections, and viral infections. Patients with fungal colonization were excluded from GEE analysis. CMV mismatch was kept in the models because of clinical importance. No interaction terms were found to be significant.
RESULTS
A total of 710 samples were collected during the period of study. The median time to Cylex ImmuKnow was 256 days (5th-75th percentile; 130 -444 days).The median number of tests per patient was three in stable states when compared with four in infected patients (PϭNS).
Demographics
Patient demographics are presented in Table 1 . The majority of lung transplant recipients were whites with me- 
Infectious Syndromes
One hundred twenty-nine infectious episodes were noted in 73 lung transplant recipients (Table 2) . Overall, 1.8% (13/710) of episodes were due to CMV infection/pneumonia followed by 0.7% (5/710) episodes of other viral infections. Fungal colonization was noted in 8.5% (61/710) of episodes, whereas fungal disease was present in 1.2% (9/710). Bacterial pneumonia accounted for 2% (14/710) of episodes, whereas tracheobronchitis was diagnosed in 3% (20/710) of episodes. No cases of empyema or surgical site infection were noted within 1 month of Cylex ImmuKnow values. The median tacrolimus values in the preceding month of infectious syndrome were 8.5 when compared with 11.5 mg/dL in stable patients (Pϭ0.09). The majority of infectious episodes occurred more than 6 months after transplant (63%, 82/129).
Test Correlation With Infections
The median value of the ImmuKnow in 581 stable episodes was 174.8 ng/mL ATP (25th-75th percentile 97-306 ng/mL ATP; Fig. 1 ).
Cytomegalovirus and Other Respiratory Viruses
A total of 13 episodes of CMV syndrome or disease were noted during the course of study. The median ImmuKnow value was 49.3 ng/mL ATP (25th-75th percentile 14 -120 ng/mL ATP). Median time to onset of CMV disease was 235 days (25th-75th percentile 166 -298 days). Six of these episodes (50%) were noted in patients who were seronegative for CMV and received an organ from CMV seropositive donor. 
Fungal Syndromes
Sixty-one episodes of fungal colonization were noted in 49 lung transplant recipients. Six patients had two episodes of In Figure 2 , we have shown a patient who had persistently lower ImmuKnow value in the event of Aspergillus colonization and subsequently developed proven invasive pulmonary aspergillosis despite having low tacrolimus levels. Although this patient did have an episode of influenza, he had recovered from it at the time of diagnosis of invasive aspergillosis.
Bacterial Infections
Fourteen episodes of bacterial pneumonia were noted in 13 patients. Of these, 11 episodes of pneumonia were due to Pseudomonas aeruginosa, whereas one episode each was noted to be due to methicillin-sensitive and -resistant Staphylococcus aureus and Escherichia coli. Median time to onset of pneumonia was 249 days (25th-75th percentile 57-337 days). The median value of ImmuKnow for pneumonia was 92.4 ng/mL ATP (25th-75th percentile 55-130 ng/mL ATP).
Twenty episodes of tracheobronchitis were diagnosed in 17 patients. Two patients had two episodes each, whereas one patient had three episodes of tracheobronchitis. Sixteen episodes of tracheobronchitis were due to P. aeruginosa, and of those, four patients had coinfection with P. aeruginosa and methicillin-resistant S. aureus, and one patient had coinfection with P. aeruginosa and Stenotrophomonas maltophilia. Median time to onset of tracheobronchitis was 589 days (25th-75th percentile 309 -672 days). The median value of ImmuKnow for pneumonia was 123 ng/mL ATP (25th-75th percentile 68 -247 ng/mL ATP).
Patients with bacterial pneumonia exhibited significantly lower ImmuKnow values than patients categorized as stable state (92.4 vs. 174 ng/mL ATP; Pϭ0.0019).
Risks hazard analysis (Fig. 3) showed increased risk of infection in transplant recipient with ImmuKnow value of less than or equal to 100, with odds ratio (OR) of 9 with values less than 50 ng/mL ATP. GEE logistic regression analysis showed ImmuKnow values of less than 100 ng/mL ATP to be an independent predictor of infections with the OR of 2.81 (Table 3) . When analyzed for bacterial, fungal, or viral infections separately, the OR was 2.4, 2.8, and 4.6, respectively. The OR for fungal disease were not significant as ORs crossed 1 (Table 3) .
DISCUSSION
Lung transplant recipients harbor the greatest risk of bacterial, fungal, and viral infections among solid organ transplant recipients (12) . The use of alemtuzumab has resulted in a favorable outcome in lung transplant recipients although the risk of infection remains significantly high (7, 13) . To optimally manage these patients, it is crucial to identify individuals who would subsequently develop infections, to use closer monitoring of immunosuppression and appropriate prophylactic strategies. Immunosuppressive drug levels commonly used to determine the net state of immunosuppression has yielded conflicting results (14, 15). Cylex ImmuKnow measures the ATP activity of activated T cells and may represent a reliable marker of immunosuppressive states in transplant recipients as the immunosuppression therapy is primarily directed against T cells. This is the largest prospective series in lung transplant recipients, whereby we show that the Cylex ImmuKnow can be used as an adjunct to determine the risk of infection. We demonstrated that major categories of infectious syndromes in lung transplant recipients are associated with differential global immunoreactivity as determined by ImmuKnow assay. Profoundly lower values were found with viral infections, which primarily require Tcell responses for adequate control when compared with fungal and bacterial infections, where the first lines of defense are components of innate immunity including macrophages and polymorphonuclear cells. Interestingly, a progression form Aspergillus colonization to the development of disease occurred exclusively in patients who exhibited lower Cylex ImmuKnow values.
Previous studies (16, 17) in small number of pancreas and small bowel transplant recipients showed that low T-cell reactivity as assessed by ImmuKnow assay with ATP levels of 100 ng/mL or less have been associated with the development of infections. Similarly, another meta-analysis involving 504 solid organ transplant recipients with 60 infectious episodes showed higher risk of infection by 12-fold in recipients with the values of 25 ng/mL ATP. These studies, however, did not use multivariate analysis and other confounders such as immunosuppressive drug levels. In contrast, in our prospective cohort of lung transplant recipients by using a robust GEE analysis, we were able to show that the ImmuKnow level of less than 100 ng/mL ATP is an independent predictor of development of infection. The values of ImmuKnow were obtained within a month of infection and the OR ranged from 2.6 to 4.6 among various infectious syndromes (Table 3) . In our study, 129 infectious episodes in 175 lung transplant recipients were noted, thus making it the largest infectious disease study reported to date. In contrast, in a recent study of heart transplant recipients (18) , the authors failed to show any correlation between the Cylex ImmuKnow values and the development of infection. However, it should be noted that only seven infectious episodes were reported in 111 cardiac transplant recipients suggesting a type II error. Furthermore, other investigators also reported in 57 lung transplant recipients (143 samples and 17 infections) an association with infection (19) , but they did not analyze ImmuKnow values as an independent predictor of infection. Interestingly, they noted lower val- ues in their African American population, which we did not see in our cohort of only 12 African American patients. Alemtuzumab induction results in profound T-cell depletion with the exception of memory cells (20, 21) . Interestingly, the median Cylex ImmuKnow values for the stable state within and after 6 months posttransplantation were not significantly different (172 vs. 178 ng/mL ATP). However, the values of Cylex ImmuKnow in infectious syndromes remained significantly different from stable states. Of note, three patients with fungal disease had increased ImmuKnow values, one patient had asymptomatic nodule, and the other two had tracheobronchitis with concomitant infection and rejection. It is plausible that these patients with tracheobronchitis may not have responded to T-cell depletion as a result of induction with alemtuzumab and indeed later developed acute rejection.
Fungal colonization with Aspergillus is a known risk factor for the development of subsequent invasive aspergillosis in lung transplant recipients; however, the positive predictive values of posttransplant Aspergillus colonization is only 28% (22, 23) . The factors responsible for progression from colonization to invasive disease are not known, resulting in universal antifungal prophylaxis in lung transplant recipients (22, 24, 25) . We noticed progression to disease only in patients who exhibited low Cylex ImmuKnow values (Ͻ50 ng/mL ATP), thus identifying a subset of individuals who might benefit most form antifungal prophylaxis and minimization of immunosuppression. However, in the multivariate risk factor analysis, the Cylex ImmuKnow value of less than hundred did not reach statistical significance to independently predict the development of fungal disease within a month of testing. We believe this is a reflection of comparatively small number of cases of fungal infections in our cohort.
We did not anticipate a correlation between Cylex ImmuKnow values with bacterial infections when compared with fungal and viral infections, because they are primarily controlled by polymorphonuclear cells and not by T cells. It is to be noted that 76% (26/34) of our patients had P. aeruginosa infection (26) .
Overall, the most significant difference of ImmuKnow values were detected among lung transplant recipients with CMV pneumonia when compared with stable patients. The lowest values for T-cell reactivity were noted in viral infections followed by fungal and then bacterial infections. Although this test is not diagnostic for the type of infection, it is correlated with global T-cell immunocompetence and increased risk of opportunistic infection primarily viral infection.
In conclusion, this is the first demonstration in a prospective cohort of lung transplant recipients that lower Cylex ImmuKnow values (Ͻ100 ng/mL ATP) independently correlate with increased risk of infection (OR 2.66). In addition, our results suggest that this test may be useful in identifying patients with fungal colonization who are at risk for progressing to fungal disease and might benefit from antifungal prophylaxis and close monitoring of immunosuppression.
